Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SEINRLF 52 Debt-to-EBITDA is -2.00 as of Mar. 2026. GuruFocus rates INRLF with a GF Score™ of 52/100 and a GF Value™ of $2.68 (Fairly Valued). The stock has 6 warning signs investors should review. Among 291 Biotechnology companies, Valneva SE ranks worse than 343642.27% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Valneva SE's Debt-to-EBITDA or its related term are showing as below:
INRLF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -55.19 Med: -1.91 Max: 15.57
Current: -2.17
During the past 13 years, the highest Debt-to-EBITDA Ratio of Valneva SE was 15.57. The lowest was -55.19. And the median was -1.91.
INRLF's Debt-to-EBITDA is ranked worse than 100% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs INRLF: -2.17
Valneva SE (OTCPK:INRLF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Valneva SE Debt-to-EBITDA Related Terms
Valneva SE Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Valneva SE's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INRLF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Valneva SE's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Valneva SE's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Valneva SE (INRLF) has a Debt-to-EBITDA of -2.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Valneva SE. According to the industry distribution chart, Valneva SE ranks #999999 out of 291 companies in the Biotechnology industry.
Is Valneva SE's Debt-to-EBITDA too high?
Valneva SE's current Debt-to-EBITDA is -2.00. Based on the distribution chart, Valneva SE ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valneva SE has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Valneva SE in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Valneva SE. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current Debt-to-EBITDA is -2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.68, compared to a current price of $2.62 — trading 2.2% below its estimated fair value. The current Debt-to-EBITDA is -2.00. Valneva SE's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Valneva SE (INRLF), the current Debt-to-EBITDA is -2.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (INRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of $2.62 is trading 2.2% below its estimated GF Value™ of $2.68.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for INRLF:
Debt-to-EBITDA: -2.00
GF Value™: $2.68 vs. price of $2.62 (2.2% below fair value)
No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
52GF Score
Get the complete analysis for INRLF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INRLF has been successfully added to your 
